Background For many inherited and acquired diseases of the blood system, ge
ne transfer into hematopoietic cells is a promising strategy to alleviate d
isease-related symptoms or even correct genetic alterations. In clinical ge
ne therapy applications, low transduction efficiencies have been a major,,
limitation mainly because of insufficient effective titers of the retrovira
l supernatants used. Thus, optimization of clinical-grade vector production
under current 'Good Manufacturing Practice' (GMP) conditions is a prerequi
site for successful gene therapy trials.
Methods We established stable retroviral producer clones with single integr
ations of a retroviral vector encoding for the multidrug-resistance gene 1
(MDR1). Optimization of vector production in multi-tray cell factories (MTC
Fs) was studied with particular regard to harvest medium, cell density and
harvest time point.
Results We demonstrated that high-titer vector stocks could be produced in
serum-free medium. By reducing the volume of harvest medium, titers could b
e increased up to four-fold. Plating optimal cell densities of I X 10(4) ce
lls/cm(2), repetitive harvests of vector supernatant were feasible over fou
r consecutive days. Combining the most advantageous culture and harvest par
ameters tested, we were able to produce large quantities of serum-free vect
or supernatant in 40-tray MTCFs. Highly efficient gene transfer into primar
y human CD34(+) progenitor cells demonstrated the quality of these vector s
tocks.
Conclusion The large-scale vector-production protocol in MTCFs described he
re is easy to handle, is applicable to a wide range of adherent producer ce
ll lines and, most importantly, complies with current GMP guidelines. Copyr
ight (C) 2001 John Wiley & Sons, Ltd.